Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline

In Vitro Selective Growth-Inhibitory Activities of Phytochemicals, Synthetic Phytochemical Analogs, and Antibiotics against Diarrheagenic/Probiotic Bacteria and Cancer/Normal Intestinal Cells

“…However, the antibacterial selectivity of nitroxoline against diarrheagenic strains was lower. Out of the intestinal bacteria tested herein, there are only data on in vitro inhibitory effects of nitroxoline against E. coli and E. faecalis that have been reported before [ 33 ]. In spite of zinc pyrithione being only used topically for dermatological infections [ 7 ], in relation to the plant compounds and their synthetic analogs in this study, it exhibited the highest growth-inhibitory activity against diarrheagenic bacteria with lowered toxicity to probiotic bacteria.…”

Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study

“…diabetes mellitus, <5% vs. 30% in the present study), and experienced mainly uncomplicated UTI, in contrast to the current study, with about half of the patients having complicated UTI. The urinary bacteriostatic activity of nitroxoline [1] does not seem to be sufficient to eradicate bacteriuria in geriatric patients, including many patients with complicated UTI. Although patients with indwelling urinary catheters were ranked as medically questionable in the present study, the microbiologic efficacy of nitroxoline in patients without catheters was also disappointing.…”

“…Letter to the Editor Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study The oral antibiotic nitroxoline 5-nitro-8-hydroxyquinoline has been licensed for urinary tract infections (UTI) since the 1960s in Germany, and because of its low resistance rates [1], it is now recommended by the 2017 German national S3 guideline as new therapeutic option in nonsevere cases of community-acquired uncomplicated UTI [2] despite the lack of prospective studies other than those published by the manufacturer [3].…”

Nitroxoline: repurposing its antimicrobial to antitumor application

“…Nevertheless, these results indicate that nitroxoline and its derivatives are suitable for use as antimicrobial agents for indications other than treatment of urinary tract infections (Cherdtrakulkiat et al, 2016). The broad antimicrobial spectrum of nitroxoline and, in general, the absence of resistance, was also observed in a recent study where the susceptibility to nitroxoline was tested against a large number of urinary clinical isolates, including those exhibiting multidrug resistance (Sobke et al, 2018). Additionally, nitroxoline has been recognized as exhibiting broad-spectrum biofilm eradication activity against several human pathogens, including those resistant to most other antimicrobial agents (Abouelhassan et al, 2017).…”

“…Additionally, nitroxoline has been recognized as exhibiting broad-spectrum biofilm eradication activity against several human pathogens, including those resistant to most other antimicrobial agents (Abouelhassan et al, 2017). Together these findings suggest novel applications for the use of nitroxoline in the treatment of bacterial infections (Cherdtrakulkiat et al, 2016;Sobke et al, 2018;Abouelhassan et al, 2017).…”